Japan Cell Therapy Market - 2026-2033
Japan Cell Therapy Market reached in and is expected to reach by , growing with a CAGR of 16.50% during the forecast period 2026-.
The Japan Cell Therapy Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Japan Cell Therapy Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Therapy Type
Both primary and secondary data sources have been used in the global Japan Cell Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Japan Cell Therapy Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Japan Cell Therapy Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Therapy Type
- Autologous cell therapy*
- Allogeneic cell therapy
- Stem cells*
- Mesenchymal stem cells (MSC)
- Induced pluripotent stem cells (iPSC)
- Hematopoietic stem cells (HSC)
- Immune cells
- T cells (CAR-T / TCR-T)
- Natural killer (NK) cells
- Others
- CAR-T cell therapy*
- TCR-T cell therapy
- NK cell therapy
- Tumor-infiltrating lymphocyte (TIL) therapy
- Stem cell regenerative therapies
- Gene-modified cell therapies
- Tissue-engineered cell products
- Oncology*
- Regenerative medicine
- Neurological disorders
- Autoimmune / inflammatory diseases
- Rare and metabolic diseases
- Peripheral blood*
- Bone marrow
- Adipose tissue
- Umbilical cord blood / cord tissue
- iPSC-derived
- In-house hospital manufacturing*
- CDMO-based manufacturing
- Centralized manufacturing
- Decentralized / point-of-care manufacturing
- Hospitals*
- Cancer treatment centers
- Regenerative medicine clinics
- Academic and research institutes
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Japan Cell Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. JAPAN CELL THERAPY MARKET—RESEARCH METHODOLOGY AND SCOPE
1.1. Research Objective and Scope of the Report
1.2. Market Definition and Coverage
1.3. Study Assumptions & Limitations
1.4. Research Methodology
1.4.1. Primary Research Approach
1.4.2. Secondary Research Sources
1.5. Data Triangulation Methodology
1.6. Market Size Estimation & Forecasting Methodology
2. JAPAN CELL THERAPY MARKET - EXECUTIVE SUMMARY
2.1. Market Size (2024-2033)
2.2. Forecast & CAGR
2.3. Key Growth Drivers, Restraints & Opportunities
2.4. High-Growth Segments & Regions
2.5. Competitive Landscape Snapshot
2.6. How This Report Supports Business Decisions
3. JAPAN CELL THERAPY MARKET - MARKET OVERVIEW
3.1. Market Evolution and Industry Context
3.2. Role of the Market within the Healthcare Ecosystem
3.3. Value Proposition & Use Cases
3.4. Key Stakeholders and End-Users
4. JAPAN CELL THERAPY MARKET - MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Market Opportunities
4.4. Industry Challenges
4.5. Impact Analysis (Short, Mid, Long Term)
5. JAPAN CELL THERAPY MARKET - DMI ANALYST OPINION
5.1. Market Evolution and Industry Context
5.2. Role of the Market within the Healthcare Ecosystem
5.3. Value Proposition & Use Cases
5.4. Key Stakeholders and End-Users
6. JAPAN CELL THERAPY MARKET - INDUSTRY & COMPETITIVE FORCES
6.1. Market Evolution and Industry Context
6.2. Role of the Market within the Healthcare Ecosystem
6.3. Value Proposition & Use Cases
6.4. Key Stakeholders and End-Users
7. JAPAN CELL THERAPY MARKET - SUPPLY CHAIN & VALUE CHAIN ANALYSIS
7.1. End-to-End Supply Chain Overview
7.1.1. Cell Sourcing and Collection
7.1.2. Cell Processing, Engineering, and Manufacturing
7.1.3. Cryopreservation, Storage, and Specialized Logistics
7.1.4. Clinical Administration and Post-Treatment Monitoring
7.1.5. Value Chain Mapping & Margin Analysis
7.2. Key Bottlenecks & Risk Factors
8. JAPAN CELL THERAPY MARKET - PRICING & COST ANALYSIS
8.1. Pricing Structure Overview
8.2. Pricing Analysis by Cell Type
8.3. Pricing Analysis by Region
8.4. Factors Influencing Price Variability
9. JAPAN CELL THERAPY MARKET– SCIENTIFIC & CLINICAL ANALYSIS
9.1. Scientific Rationale & Mechanism of Action
9.2. Clinical Evidence Overview
9.3. Role of Scientific Validation in Adoption
10. JAPAN CELL THERAPY MARKET– CLINICAL TRIALS LANDSCAPE
10.1. Country-Specific Clinical Trials Overview
10.2. Clinical Trials by Phase
10.3. Clinical Trials by Cell Type
10.4. Key Sponsors & Institutions
10.5. DMI Clinical Trial Insights
11. JAPAN CELL THERAPY MARKET - STAKEHOLDER INSIGHTS
11.1. Stakeholder Framework
11.1.1. Patients
11.1.2. Physicians / HCPs
11.1.3. Hospitals & Procurement
11.1.4. Payers / Insurers
11.2. Decision Drivers & Adoption Barriers
11.3. Price Sensitivity & Brand Preference
11.4. Unmet Needs & Opportunity Areas
12. JAPAN CELL THERAPY MARKET - DEMAND GENERATION & GO-TO-MARKET INTELLIGENCE
12.1. Demand Drivers by Segment
12.2. Awareness vs Adoption Gap Analysis
12.3. Key Customer Acquisition Channels
12.4. Commercialization & Market Entry Insights
13. JAPAN CELL THERAPY MARKET– IMPORT & EXPORT ANALYSIS
13.1. Trade Flow Overview
13.2. HS Code Mapping
13.3. Trade Dependency & Risk Analysis
13.3.1. Note: Country & year-level customization available
14. JAPAN CELL THERAPY MARKET -SUSTAINABILITY & ESG ANALYSIS
14.1. ESG Trends Impacting the Market
14.2. Regulatory & Compliance Requirements
14.3. Sustainable Sourcing & Manufacturing Practices
14.4. DMI Clinical Trial Insights
15. JAPAN CELL THERAPY MARKET– PARTNERSHIP & ECOSYSTEM MAPPING
15.1. Ecosystem Overview
15.2. Potential Distribution & Channel Partners
15.3. Manufacturing & Technology Partnerships
15.4. CRO / Hospital / Institutional Collaborations
16. JAPAN CELL THERAPY MARKET - MARKET SEGMENTATION ANALYSIS
16.1. Market Segmentation Overview
16.2. Market Size Analysis:
16.2.1. By Therapy Type
16.2.2. By Cell Type
16.2.3. By Technology / Product Type
16.2.4. By Therapeutic Application
16.2.5. By Source of Cells
16.2.6. By Manufacturing Model
16.2.7. By End User
16.3. Market Attractiveness Analysis
17. JAPAN CELL THERAPY MARKET– BY THERAPY TYPE
17.1. Introduction
17.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
17.1.2. Market Attractiveness Index, By Therapy Type
17.2. Autologous cell therapy*
17.2.1. Introduction
17.2.2. Market Size Analysis, US$ Million, 2024-2033 and Y-o-Y Growth Analysis (%), 2026-2033
17.3. Allogeneic cell therapy
18. JAPAN CELL THERAPY MARKET– BY CELL TYPE
18.1. Introduction
18.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
18.1.2. Market Attractiveness Index, By Cell Type
18.2. Stem cells*
18.2.1. Introduction
18.2.2. Market Size Analysis, US$ Million, 2024-2033 and Y-o-Y Growth Analysis (%), 2026-2033
18.2.3. Mesenchymal stem cells (MSC)
18.2.4. Induced pluripotent stem cells (iPSC)
18.2.5. Hematopoietic stem cells (HSC)
18.3. Immune cells
18.3.1. T cells (CAR-T / TCR-T)
18.3.2. Natural killer (NK) cells
18.4. Others
19. JAPAN CELL THERAPY MARKET–BY TECHNOLOGY/PRODUCT TYPE
19.1. Introduction
19.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology/Product Type
19.1.2. Market Attractiveness Index, By Technology/Product Type
19.2. CAR-T cell therapy*
19.2.1. Introduction
19.2.2. Market Size Analysis, US$ Million, 2024-2033 and Y-o-Y Growth Analysis (%), 2026-2033
19.3. TCR-T cell therapy
19.4. NK cell therapy
19.5. Tumor-infiltrating lymphocyte (TIL) therapy
19.6. Stem cell regenerative therapies
19.7. Gene-modified cell therapies
19.8. Tissue-engineered cell products
20. JAPAN CELL THERAPY MARKET–BY THERAPEUTIC APPLICATION
20.1. Introduction
20.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
20.1.2. Market Attractiveness Index, By Therapeutic Application
20.2. Oncology*
20.2.1. Introduction
20.2.2. Market Size Analysis, US$ Million, 2024-2033 and Y-o-Y Growth Analysis (%), 2026-2033
20.3. Regenerative medicine
20.4. Neurological disorders
20.5. Autoimmune / inflammatory diseases
20.6. Rare and metabolic diseases
21. JAPAN CELL THERAPY MARKET–BY SOURCE OF CELLS
21.1. Introduction
21.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source of Cells
21.1.2. Market Attractiveness Index, By Source of Cells
21.2. Peripheral blood*
21.2.1. Introduction
21.2.2. Market Size Analysis, US$ Million, 2024-2033 and Y-o-Y Growth Analysis (%), 2026-2033
21.3. Bone marrow
21.4. Adipose tissue
21.5. Umbilical cord blood / cord tissue
21.6. iPSC-derived
22. JAPAN CELL THERAPY MARKET–BY MANUFACTURING MODEL
22.1. Introduction
22.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Model
22.1.2. Market Attractiveness Index, By Manufacturing Model
22.2. In-house hospital manufacturing*
22.2.1. Introduction
22.2.2. Market Size Analysis, US$ Million, 2024-2033 and Y-o-Y Growth Analysis (%), 2026-2033
22.3. CDMO-based manufacturing
22.4. Centralized manufacturing
22.5. Decentralized / point-of-care manufacturing
23. JAPAN CELL THERAPY MARKET–BY END USER
23.1. Introduction
23.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
23.1.2. Market Attractiveness Index, By End-User
23.2. Hospitals*
23.2.1. Introduction
23.2.2. Market Size Analysis, US$ Million, 2024-2033 and Y-o-Y Growth Analysis (%), 2026-2033
23.3. Cancer treatment centers
23.4. Regenerative medicine clinics
23.5. Academic and research institutes
24. JAPAN CELL THERAPY MARKET - COMPETITIVE LANDSCAPE
24.1. Market Share Analysis
24.2. Competitive Positioning Matrix
24.3. Key Strategic Initiatives
24.4. Emerging Players & Startups
25. JAPAN CELL THERAPY MARKET - COMPANY PROFILES
25.1. FUJIFILM Cellular Dynamics, Inc.
25.1.1. Company Overview
25.1.2. Product Portfolio
25.1.3. Financial Performance
25.1.4. Recent Developments & Strategies
25.1.5. Takara Bio Inc.
25.1.6. Healios K.K.
25.1.7. Sumitomo Pharma Co., Ltd.
25.1.8. JCR Pharmaceuticals Co., Ltd.
25.1.9. Terumo Corporation
25.1.10. Japan Tissue Engineering Co., Ltd. (J-TEC)
25.1.11. Teijin Limited
25.1.12. Nikon Corporation (Nikon CeLL Innovation)
25.1.13. AGC Inc.
25.1.14. Daiichi Sankyo Company, Limited
25.1.15. Astellas Pharma Inc.
25.1.16. Chugai Pharmaceutical Co., Ltd.
25.1.17. Kyowa Kirin Co., Ltd.
25.1.18. "Rakuten Medical K.K."
25.1.19. Heartseed Inc.
25.1.20. CellSeed Inc.
25.1.21. ReproCELL Inc.
25.1.22. Nipro Corporation (LIST NOT EXHAUSTIVE)
26. JAPAN CELL THERAPY MARKET - APPENDIX
26.1. About Us and Services
26.2. Contact Us
1.1. Research Objective and Scope of the Report
1.2. Market Definition and Coverage
1.3. Study Assumptions & Limitations
1.4. Research Methodology
1.4.1. Primary Research Approach
1.4.2. Secondary Research Sources
1.5. Data Triangulation Methodology
1.6. Market Size Estimation & Forecasting Methodology
2. JAPAN CELL THERAPY MARKET - EXECUTIVE SUMMARY
2.1. Market Size (2024-2033)
2.2. Forecast & CAGR
2.3. Key Growth Drivers, Restraints & Opportunities
2.4. High-Growth Segments & Regions
2.5. Competitive Landscape Snapshot
2.6. How This Report Supports Business Decisions
3. JAPAN CELL THERAPY MARKET - MARKET OVERVIEW
3.1. Market Evolution and Industry Context
3.2. Role of the Market within the Healthcare Ecosystem
3.3. Value Proposition & Use Cases
3.4. Key Stakeholders and End-Users
4. JAPAN CELL THERAPY MARKET - MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Market Opportunities
4.4. Industry Challenges
4.5. Impact Analysis (Short, Mid, Long Term)
5. JAPAN CELL THERAPY MARKET - DMI ANALYST OPINION
5.1. Market Evolution and Industry Context
5.2. Role of the Market within the Healthcare Ecosystem
5.3. Value Proposition & Use Cases
5.4. Key Stakeholders and End-Users
6. JAPAN CELL THERAPY MARKET - INDUSTRY & COMPETITIVE FORCES
6.1. Market Evolution and Industry Context
6.2. Role of the Market within the Healthcare Ecosystem
6.3. Value Proposition & Use Cases
6.4. Key Stakeholders and End-Users
7. JAPAN CELL THERAPY MARKET - SUPPLY CHAIN & VALUE CHAIN ANALYSIS
7.1. End-to-End Supply Chain Overview
7.1.1. Cell Sourcing and Collection
7.1.2. Cell Processing, Engineering, and Manufacturing
7.1.3. Cryopreservation, Storage, and Specialized Logistics
7.1.4. Clinical Administration and Post-Treatment Monitoring
7.1.5. Value Chain Mapping & Margin Analysis
7.2. Key Bottlenecks & Risk Factors
8. JAPAN CELL THERAPY MARKET - PRICING & COST ANALYSIS
8.1. Pricing Structure Overview
8.2. Pricing Analysis by Cell Type
8.3. Pricing Analysis by Region
8.4. Factors Influencing Price Variability
9. JAPAN CELL THERAPY MARKET– SCIENTIFIC & CLINICAL ANALYSIS
9.1. Scientific Rationale & Mechanism of Action
9.2. Clinical Evidence Overview
9.3. Role of Scientific Validation in Adoption
10. JAPAN CELL THERAPY MARKET– CLINICAL TRIALS LANDSCAPE
10.1. Country-Specific Clinical Trials Overview
10.2. Clinical Trials by Phase
10.3. Clinical Trials by Cell Type
10.4. Key Sponsors & Institutions
10.5. DMI Clinical Trial Insights
11. JAPAN CELL THERAPY MARKET - STAKEHOLDER INSIGHTS
11.1. Stakeholder Framework
11.1.1. Patients
11.1.2. Physicians / HCPs
11.1.3. Hospitals & Procurement
11.1.4. Payers / Insurers
11.2. Decision Drivers & Adoption Barriers
11.3. Price Sensitivity & Brand Preference
11.4. Unmet Needs & Opportunity Areas
12. JAPAN CELL THERAPY MARKET - DEMAND GENERATION & GO-TO-MARKET INTELLIGENCE
12.1. Demand Drivers by Segment
12.2. Awareness vs Adoption Gap Analysis
12.3. Key Customer Acquisition Channels
12.4. Commercialization & Market Entry Insights
13. JAPAN CELL THERAPY MARKET– IMPORT & EXPORT ANALYSIS
13.1. Trade Flow Overview
13.2. HS Code Mapping
13.3. Trade Dependency & Risk Analysis
13.3.1. Note: Country & year-level customization available
14. JAPAN CELL THERAPY MARKET -SUSTAINABILITY & ESG ANALYSIS
14.1. ESG Trends Impacting the Market
14.2. Regulatory & Compliance Requirements
14.3. Sustainable Sourcing & Manufacturing Practices
14.4. DMI Clinical Trial Insights
15. JAPAN CELL THERAPY MARKET– PARTNERSHIP & ECOSYSTEM MAPPING
15.1. Ecosystem Overview
15.2. Potential Distribution & Channel Partners
15.3. Manufacturing & Technology Partnerships
15.4. CRO / Hospital / Institutional Collaborations
16. JAPAN CELL THERAPY MARKET - MARKET SEGMENTATION ANALYSIS
16.1. Market Segmentation Overview
16.2. Market Size Analysis:
16.2.1. By Therapy Type
16.2.2. By Cell Type
16.2.3. By Technology / Product Type
16.2.4. By Therapeutic Application
16.2.5. By Source of Cells
16.2.6. By Manufacturing Model
16.2.7. By End User
16.3. Market Attractiveness Analysis
17. JAPAN CELL THERAPY MARKET– BY THERAPY TYPE
17.1. Introduction
17.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
17.1.2. Market Attractiveness Index, By Therapy Type
17.2. Autologous cell therapy*
17.2.1. Introduction
17.2.2. Market Size Analysis, US$ Million, 2024-2033 and Y-o-Y Growth Analysis (%), 2026-2033
17.3. Allogeneic cell therapy
18. JAPAN CELL THERAPY MARKET– BY CELL TYPE
18.1. Introduction
18.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
18.1.2. Market Attractiveness Index, By Cell Type
18.2. Stem cells*
18.2.1. Introduction
18.2.2. Market Size Analysis, US$ Million, 2024-2033 and Y-o-Y Growth Analysis (%), 2026-2033
18.2.3. Mesenchymal stem cells (MSC)
18.2.4. Induced pluripotent stem cells (iPSC)
18.2.5. Hematopoietic stem cells (HSC)
18.3. Immune cells
18.3.1. T cells (CAR-T / TCR-T)
18.3.2. Natural killer (NK) cells
18.4. Others
19. JAPAN CELL THERAPY MARKET–BY TECHNOLOGY/PRODUCT TYPE
19.1. Introduction
19.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology/Product Type
19.1.2. Market Attractiveness Index, By Technology/Product Type
19.2. CAR-T cell therapy*
19.2.1. Introduction
19.2.2. Market Size Analysis, US$ Million, 2024-2033 and Y-o-Y Growth Analysis (%), 2026-2033
19.3. TCR-T cell therapy
19.4. NK cell therapy
19.5. Tumor-infiltrating lymphocyte (TIL) therapy
19.6. Stem cell regenerative therapies
19.7. Gene-modified cell therapies
19.8. Tissue-engineered cell products
20. JAPAN CELL THERAPY MARKET–BY THERAPEUTIC APPLICATION
20.1. Introduction
20.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
20.1.2. Market Attractiveness Index, By Therapeutic Application
20.2. Oncology*
20.2.1. Introduction
20.2.2. Market Size Analysis, US$ Million, 2024-2033 and Y-o-Y Growth Analysis (%), 2026-2033
20.3. Regenerative medicine
20.4. Neurological disorders
20.5. Autoimmune / inflammatory diseases
20.6. Rare and metabolic diseases
21. JAPAN CELL THERAPY MARKET–BY SOURCE OF CELLS
21.1. Introduction
21.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source of Cells
21.1.2. Market Attractiveness Index, By Source of Cells
21.2. Peripheral blood*
21.2.1. Introduction
21.2.2. Market Size Analysis, US$ Million, 2024-2033 and Y-o-Y Growth Analysis (%), 2026-2033
21.3. Bone marrow
21.4. Adipose tissue
21.5. Umbilical cord blood / cord tissue
21.6. iPSC-derived
22. JAPAN CELL THERAPY MARKET–BY MANUFACTURING MODEL
22.1. Introduction
22.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Model
22.1.2. Market Attractiveness Index, By Manufacturing Model
22.2. In-house hospital manufacturing*
22.2.1. Introduction
22.2.2. Market Size Analysis, US$ Million, 2024-2033 and Y-o-Y Growth Analysis (%), 2026-2033
22.3. CDMO-based manufacturing
22.4. Centralized manufacturing
22.5. Decentralized / point-of-care manufacturing
23. JAPAN CELL THERAPY MARKET–BY END USER
23.1. Introduction
23.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
23.1.2. Market Attractiveness Index, By End-User
23.2. Hospitals*
23.2.1. Introduction
23.2.2. Market Size Analysis, US$ Million, 2024-2033 and Y-o-Y Growth Analysis (%), 2026-2033
23.3. Cancer treatment centers
23.4. Regenerative medicine clinics
23.5. Academic and research institutes
24. JAPAN CELL THERAPY MARKET - COMPETITIVE LANDSCAPE
24.1. Market Share Analysis
24.2. Competitive Positioning Matrix
24.3. Key Strategic Initiatives
24.4. Emerging Players & Startups
25. JAPAN CELL THERAPY MARKET - COMPANY PROFILES
25.1. FUJIFILM Cellular Dynamics, Inc.
25.1.1. Company Overview
25.1.2. Product Portfolio
25.1.3. Financial Performance
25.1.4. Recent Developments & Strategies
25.1.5. Takara Bio Inc.
25.1.6. Healios K.K.
25.1.7. Sumitomo Pharma Co., Ltd.
25.1.8. JCR Pharmaceuticals Co., Ltd.
25.1.9. Terumo Corporation
25.1.10. Japan Tissue Engineering Co., Ltd. (J-TEC)
25.1.11. Teijin Limited
25.1.12. Nikon Corporation (Nikon CeLL Innovation)
25.1.13. AGC Inc.
25.1.14. Daiichi Sankyo Company, Limited
25.1.15. Astellas Pharma Inc.
25.1.16. Chugai Pharmaceutical Co., Ltd.
25.1.17. Kyowa Kirin Co., Ltd.
25.1.18. "Rakuten Medical K.K."
25.1.19. Heartseed Inc.
25.1.20. CellSeed Inc.
25.1.21. ReproCELL Inc.
25.1.22. Nipro Corporation (LIST NOT EXHAUSTIVE)
26. JAPAN CELL THERAPY MARKET - APPENDIX
26.1. About Us and Services
26.2. Contact Us
